Tetra Bio-Pharma Inc. (JAM1.F)
Chart Events
Performance Outlook
| Previous Close | 0.1660 |
| Open | 0.1488 |
| Bid | 0.0000 x 4074100 |
| Ask | 0.0000 x 2558200 |
| Day's Range | 0.1488 - 0.1488 |
| 52 Week Range | 0.0898 - 0.3525 |
| Volume | 35,000 |
| Avg. Volume | 6,320 |
| Market Cap | 65.805M |
| Beta (5Y Monthly) | 2.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- PR Newswire
Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today provided an update on the progress and significant achievements of its lead investigational drug, QIXLEEF™.
- PR Newswire
REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that numerous pre-launch activities for REDUVO™ have been initiated. REDUVO™ is a cannabinoid-derived drug indicated in chemotherapy-induced nausea and vomiting (CINV). In December 2020, the Company submitted a New Drug Submission to Health Canada which is currently in its final stage of review by the regulator.
- PR Newswire
Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development is pleased to announce that it received the Scientific Advice Assessment (SAA) Report from the Malta Medicines Authority. Overall, the SAA Report provided positive feedback on Tetra's drug development plan for QIXLEEF™ and eligibility for submitting a Marketing Authorization Application (MAA) under Directive 2001/83/EC (Directive). QIXLEEF™ is the
